SM 04755

Drug Profile

SM 04755

Alternative Names: SM04755

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Samumed
  • Class Antineoplastics
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Gastric cancer; Liver cancer; Pancreatic cancer
  • Preclinical Psoriasis; Scleroderma; Tendinitis

Most Recent Events

  • 16 Nov 2016 Samumed plans a phase II trial for Psoriasis in 2017
  • 14 Nov 2016 Samumed opens an IND for Tendinitis in USA
  • 14 Nov 2016 Pharmacodynamics data from a preclinical study in Tendinitis released by Samumed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top